Table 5. Clinical features and outcome of Epsiten-Barr virus-positive mucocutaneous ulcer (EBVMCU).
| Subtype | Author | Year | N | Sex | Age | Basal disease | MTX duration | Tumor sites | Pattern | LPD therapy | Alive /Dead |
OS (M) | Ref | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Types | Duration | ||||||||||||||||||||||||||||||||||
| M | F | Mean | Range | RA | Other | Mean | Range | Mean | Range | oral | skin | tongue | eyelid | other | R | R/R | P | Ch | A | D | Mean | Range | |||||||||||||
| MTX-EBVMCU | Satoh | 2009 | 1 | 0 | 1 | 73 | - | 1 | - | NR | 5 | - | 0 | 0 | 0 | 0 | Gastric | 1 | 0 | 0 | 0 | 1 | 0 | 8 | - | 87 | |||||||||
| Dojcinov | 2010 | 1 | 0 | 1 | 80 | - | 1 | - | NR | NR | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 60 | - | 78 | ||||||||||||
| Attard | 2012 | 1 | 0 | 1 | 81 | - | 1 | NR | NR | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 12 | - | 88 | |||||||||||||
| Hashizume | 2012 | 1 | 0 | 1 | 62 | - | 0 | DM 1 | NR | 7 | - | 0 | 0 | 0 | 1 | (+Lip, Nose) | 1 | 0 | 0 | 0 | 1 | 0 | 1 | - | 89 | ||||||||||
| Yamakawa | 2014 | 5 | 0 | 5 | 63 | 56-76 | 4 | PM 1 | NR | 4.8 | 0.3-10 | 0 | 2 | 0 | 2 | Bucca Mucosa | 4 | 0 | 0 | 1* | * R-CHOP | 4 | 0 | 24 | 1-37 | 42 | |||||||||
| Sadasivam | 2014 | 1 | 0 | 1 | 66 | - | 1 | NR | NR | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 19 | - | 90 | |||||||||||||
| Moran | 2015 | 1 | 0 | 1 | 53 | - | 0 | CD 1 | NR | 1 | - | 0 | 0 | 0 | 0 | Colon, Rectum | 0 | 1* | 0 | 0 | * ABVD | 1 | 0 | 24 | - | 91 | |||||||||
| Hashimoto | 2015 | 2 | 0 | 2 | 74 | 74, 74 | 2 | - | 3.2 | 0.5, 6 | 2.7 | 0.5, 5 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 30 | 12-48 | 92 | ||||||||||
| Nakauyaca | 2016 | 1 | 0 | 1 | 67 | - | 1 | - | 20 | - | 20 | - | 0 | 0 | 1 | 0 | 0 | 0 | 1* | 0 | * No therapy due to death | 0 | 1 | 0 | - | 93 | |||||||||
| Chen | 2017 | 1 | 0 | 1 | 58 | - | 1 | - | NR | NR | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 9 | - | 94 | ||||||||||||
| Furudate | 2017 | 1 | 1 | 0 | 74 | - | 1 | - | NR | 7 | - | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 24 | - | 95 | |||||||||||
| Daroontum | 2018 | 7 | 0 | 7 | 75 | 61-85 | 6 | SjS 1 | 10 | 2-22 | 4 | 2-10 | 4 | 2 | 1 | 0 | 6 | 0 | 1* | 0 | * R-CHOP | 7 | 0 | 40 | 31-81 | 96 | |||||||||
| Satou | 2018 | 9 | 4 | 5 | 72 | 48-87 | 9 | - | NR | 8.3 | 4-19 | 8 | 0 | 1 | 0 | 7 | 0 | 2* | 0 | * R-CHOP, ABVD | 9 | 0 | 45 | 8-139 | 97 | ||||||||||
| Total | 32 | 5 | 27 | 70 | 28 | 4 | 9.4 | 6.3 | 17 | 5 | 4 | 3 | 3 | 26 | 1 | 4 | 1 | 31 | 1 | 32 | |||||||||||||||
ND, not described; RA, rheumatoid arthritis; PM, polymyositis; PV, psoriasis vulgaris. EBV, Epstein-Barr virus; ND, not described; DM, dermatomyositis; PM, polymyositis; CD, Crohn disease; R, regressive group; R/R, relapse/regrowth group; P. persistent group; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone; ABVD, doxorubicin, bleomycin, vinblastine and dacarbazine; A, alive; D, dead: OS ,overall survival; Ref, reference.